CARTESIAN THERAPEUTICS INC (RNAC)
US8162123025 - Common Stock
We assign a fundamental rating of 3 out of 10 to RNAC. RNAC was compared to 565 industry peers in the Biotechnology industry. RNAC has a great financial health rating, but its profitability evaluates not so good. RNAC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year RNAC has reported negative net income.
In the past year RNAC has reported a negative cash flow from operations.
In the past 5 years RNAC reported 4 times negative net income.
In the past 5 years RNAC reported 4 times negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -54.70%, RNAC perfoms like the industry average, outperforming 44.03% of the companies in the same industry.
Looking at the Return On Equity, with a value of -33116.62%, RNAC is doing worse than 84.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -54.7% | ||
| ROE | -33116.62% | ||
| ROIC | N/A |
ROA(3y)-22.25%
ROA(5y)-32.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for RNAC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RNAC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RNAC has been increased compared to 1 year ago.
The number of shares outstanding for RNAC has been increased compared to 5 years ago.
There is no outstanding debt for RNAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RNAC has an Altman-Z score of -1.26. This is a bad value and indicates that RNAC is not financially healthy and even has some risk of bankruptcy.
RNAC's Altman-Z score of -1.26 is in line compared to the rest of the industry. RNAC outperforms 58.65% of its industry peers.
There is no outstanding debt for RNAC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.26 |
ROIC/WACCN/A
WACC10.56%
2.3 Liquidity
A Current Ratio of 10.70 indicates that RNAC has no problem at all paying its short term obligations.
With an excellent Current ratio value of 10.70, RNAC belongs to the best of the industry, outperforming 83.60% of the companies in the same industry.
RNAC has a Quick Ratio of 10.70. This indicates that RNAC is financially healthy and has no problem in meeting its short term obligations.
RNAC's Quick ratio of 10.70 is amongst the best of the industry. RNAC outperforms 83.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.7 | ||
| Quick Ratio | 10.7 |
3. Growth
3.1 Past
The earnings per share for RNAC have decreased strongly by -91.16% in the last year.
The Revenue has grown by 38.82% in the past year. This is a very strong growth!
Measured over the past years, RNAC shows a very strong growth in Revenue. The Revenue has been growing by 95.83% on average per year.
EPS 1Y (TTM)-91.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.22%
Revenue 1Y (TTM)38.82%
Revenue growth 3Y16.15%
Revenue growth 5Y95.83%
Sales Q2Q%-94.09%
3.2 Future
RNAC is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.93% yearly.
The Revenue is expected to grow by 13.02% on average over the next years. This is quite good.
EPS Next Y52.75%
EPS Next 2Y28.3%
EPS Next 3Y15.99%
EPS Next 5Y4.93%
Revenue Next Year88.04%
Revenue Next 2Y-43.46%
Revenue Next 3Y-21.73%
Revenue Next 5Y13.02%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
RNAC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RNAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RNAC's earnings are expected to grow with 15.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.3%
EPS Next 3Y15.99%
5. Dividend
5.1 Amount
No dividends for RNAC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARTESIAN THERAPEUTICS INC
NASDAQ:RNAC (11/20/2024, 8:00:02 PM)
After market: 16.94 0 (0%)16.94
-0.61 (-3.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap430.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -54.7% | ||
| ROE | -33116.62% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 10.7 | ||
| Quick Ratio | 10.7 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-91.16%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y52.75%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)38.82%
Revenue growth 3Y16.15%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y